Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)

G A Hitman; H Colhoun; C Newman; M Szarek; D J Betteridge; P N Durrington; J Fuller; S Livingstone; H A W Neil; CARDS Investigators

doi:10.1111/j.1464-5491.2007.02268.x

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)

G A Hitman, H Colhoun, C Newman, M Szarek, D J Betteridge, P N Durrington, J Fuller, S Livingstone, H A W Neil, CARDS Investigators

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Patients with Type 2 diabetes have an elevated risk of stroke. The role of lipid levels and diabetes-specific factors in risk prediction of stroke is unclear, and estimates of efficacy of lipid-lowering therapy vary between trials. We examined predictors of stroke and the effect of atorvastatin on specific stroke subtypes in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) [a trial of 2838 participants with mean low-density lipoprotein cholesterol <4.14 mmol/l, no history of macrovascular disease and randomized to atorvastatin 10 mg daily or placebo].

Original language	English
Pages (from-to)	1313-1321
Number of pages	9
Journal	Diabetic Medicine
Volume	24
Issue number	12
DOIs	https://doi.org/10.1111/j.1464-5491.2007.02268.x
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1464-5491.2007.02268.x

Cite this

@article{a7cf75afda6b4e6aa7a716c9aef6a6a1,

title = "Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)",

abstract = "Patients with Type 2 diabetes have an elevated risk of stroke. The role of lipid levels and diabetes-specific factors in risk prediction of stroke is unclear, and estimates of efficacy of lipid-lowering therapy vary between trials. We examined predictors of stroke and the effect of atorvastatin on specific stroke subtypes in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) [a trial of 2838 participants with mean low-density lipoprotein cholesterol <4.14 mmol/l, no history of macrovascular disease and randomized to atorvastatin 10 mg daily or placebo].",

author = "Hitman, {G A} and H Colhoun and C Newman and M Szarek and Betteridge, {D J} and Durrington, {P N} and J Fuller and S Livingstone and Neil, {H A W} and {CARDS Investigators}",

year = "2007",

doi = "10.1111/j.1464-5491.2007.02268.x",

language = "English",

volume = "24",

pages = "1313--1321",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley",

number = "12",

}

TY - JOUR

T1 - Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)

AU - Hitman, G A

AU - Colhoun, H

AU - Newman, C

AU - Szarek, M

AU - Betteridge, D J

AU - Durrington, P N

AU - Fuller, J

AU - Livingstone, S

AU - Neil, H A W

AU - CARDS Investigators

PY - 2007

Y1 - 2007

N2 - Patients with Type 2 diabetes have an elevated risk of stroke. The role of lipid levels and diabetes-specific factors in risk prediction of stroke is unclear, and estimates of efficacy of lipid-lowering therapy vary between trials. We examined predictors of stroke and the effect of atorvastatin on specific stroke subtypes in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) [a trial of 2838 participants with mean low-density lipoprotein cholesterol <4.14 mmol/l, no history of macrovascular disease and randomized to atorvastatin 10 mg daily or placebo].

AB - Patients with Type 2 diabetes have an elevated risk of stroke. The role of lipid levels and diabetes-specific factors in risk prediction of stroke is unclear, and estimates of efficacy of lipid-lowering therapy vary between trials. We examined predictors of stroke and the effect of atorvastatin on specific stroke subtypes in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) [a trial of 2838 participants with mean low-density lipoprotein cholesterol <4.14 mmol/l, no history of macrovascular disease and randomized to atorvastatin 10 mg daily or placebo].

U2 - 10.1111/j.1464-5491.2007.02268.x

DO - 10.1111/j.1464-5491.2007.02268.x

M3 - Article

C2 - 17894827

SN - 0742-3071

VL - 24

SP - 1313

EP - 1321

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 12

ER -

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this